At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
RVF MP-12biological
Likely dose
RVF MP-12 1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study
U.S. Army Medical Research and Development Command·interventional·Posted Dec 22, 2006·Updated Jan 3, 2020
In Brief
A Phase 2 clinical trial evaluating RVF MP-12 for Rift Valley Fever. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRift Valley Fever
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedDec 2006
Primary CompletionMay 2008
Study CompletionMay 2009
TodayJul 2026
First PostedDec 22, 2006
Enrollment StartAug 1, 2006
Primary CompletionMay 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.5 years ago
Interventions
RVF MP-12biological
Administer 1 ml SQ